FDA Approves IMATINIB MESYLATE — BluePoint Laboratories

# FDA Approves Generic Imatinib Mesylate by BluePoint Laboratories BluePoint Laboratories received FDA approval for its generic formulation of imatinib mesylate, a breakthrough tyrosine kinase inhibitor used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, potentially expanding patient access while intensifying pricing competition in the oral oncology market. The approval of this generic alternative to Novartis's Gleevec could significantly reduce treatment costs for patients and payers, though it may pressure revenues for branded imatinib products currently